logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Empaglifozin for treatment of chronic heart failure with reduced ejection fraction

< Back

Empaglifozin for treatment of chronic heart failure with reduced ejection fraction

Drugs

Cardiovascular Disease and Vascular Surgery

June 2020


Empagliflozin is currently in clinical development for the treatment of heart failure (HF) with reduced ejection fraction. HF is a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart to pump blood around the body is impaired. Symptoms of HF include breathlessness, fatigue and ankle swelling, and signs of the condition include crackling sounds in the lungs or excess fluid in the lungs. More than half of people with HF have reduced ejection fraction (HRrEF), also referred to as systolic HF. This means that the heart muscle does not contract effectively and therefore less oxygen-rich blood is pumped out to the body. There remains a large unmet need for new therapies in the treatment of HRrEF.

Empagliflozin is given by mouth in the form of a tablet and works by inhibiting the sodium transporter NHE1. This prevents salt from being re-absorbed so there is increased excretion of salt from the body and a reduced volume of fluid in the blood vessels. It’s thought that these changes in sugar, salt and water metabolism in the body may contribute to the reductions in cardiovascular death. If licensed, empagliflozin may provide an additional treatment option for people with HFrEF who currently have limited therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts